Novartis to Invest 140 Billion Won in Korea’s Radioligand Therapy Supply Chain
Health and Welfare Minister Jung Eun-kyeong (left) and Judith Love, President of Novartis Asia Pacific, Middle East and…
Meet Colin: A Novartis Scientist Looking for New Breakthroughs
Colin works in San Diego, where we’ve recently broken ground on a new, state-of-the-art global Biomedical Research center…
Carter’s Story: My Mom’s Journey with Cancer Inspired Me. Now I Help Make Medicines for Patients
Carter Jaynes, one of our RLT production managers, recently made a move across the country: He brought his…
Pushing the prostate cancer treatment frontier: Radioligand therapy and beyond
Radioligand therapy (RLT) has been a breakthrough, practice-changing therapy in prostate cancer. While it has improved outcomes, Novartis…
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Novartis Pharma AG Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic…
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
Novartis Pharma AG At one-year mark, company has progressed all components of US investment plan to support delivery…
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
Novartis Pharma AG US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark…
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Pluvicto®PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancer Kisqali®…
Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA
Novartis Pharma AG Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic…
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
Novartis Pharma AG US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark…
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
Novartis Pharma AG US Under Secretary of Commerce Jeffrey Kessler, Texas State Senator Brent Hagenbuch, Novartis leadership mark…
Novartis Expands US Radioligand Network And Manufacturing For Future Growth
Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…